INTRODUCTION {#s1}
============

Comprehensive sequencing efforts over the past decade have confirmed that cancer is a disease of the genome \[[@R1]\]. Genomic alterations in cancers include point mutations, insertions and deletions (indels), structural variations, copy number alterations, epigenetic changes, and microbial infections. Abnormalities in oncogenes and tumor suppressors act as driver mutations to initiate the onset and progression of cancers. Technically, these alterations are identified by comparing the cancer genome sequence with a reference human genome and excluding those also found in normal controls (counterpart normal tissues or peripheral blood) and single nucleotide polymorphisms (SNPs) \[[@R2]\]. This strategy is effective to uncover somatic genomic alterations in tumor tissues. However, whether there is any genomic alteration in counterpart normal controls (CNCs) but not cancer tissues, remains unclear.

Lung cancer is the most common cause of cancer related mortality worldwide \[[@R3]\] and can be divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC comprises of lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and large cell carcinoma \[[@R4]\]. It is estimated that 90% of lung cancer deaths are caused by cigarette smoke \[[@R5]\], whereas SCLC and LUSC are most strongly linked with smoking \[[@R4]\]. Since the late 1980s, LUAD has become the most common type (40%) of lung cancer that is related to cigarette smoke due to the changes in cigarette composition and filtering which favor adenocarcinoma histology \[[@R6]\]. There is also a proportion of LUADs that is not associated with smoking \[[@R4]\], while air pollution represents another cause of lung cancer which induces somatic mutations in the genomes \[[@R7]\]. The cellular injury produced by smoking involves the whole respiratory tract \[[@R8], [@R9]\]; in the initial phase of lung carcinogenesis, injury is repaired by stem/progenitor cells, forming a clonal group of self-renewing daughter cells. Accumulation of genetic alterations in the premalignant field results in proliferation of the cells and expansion of the field, gradually displacing the normal epithelium and developing into a malignant neoplasm \[[@R10]--[@R12]\]. Genomic alterations of LUADs had been characterized and druggable targets had been unveiled \[[@R13], [@R14]\]. However, very few studies systematically dissect genomic mutations specifically occurred in "normal" lung tissues and their roles in carcinogenesis, and no study reports how the adjacent tissues escape from developing into malignant neoplasms.

In our work analyzing somatic genomic mutations in air pollution-related lung cancers \[[@R7]\], we noted that when compared with the reference human genome, some variations were seen in counterpart normal lung tissues but not cancer samples (Table [1](#T1){ref-type="table"}). To expand these observations, we further analyzed the Cancer Genome Atlas (TCGA) lung cancer genome data of 513 CNCs and counterpart tumor samples ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). Our results showed that the CNCs did harbor some genomic variations.

###### Genomic variations in CNCs of 11 patients with LUAD

  Pt \#   Gene         Chr   Start       End         Ref                        Alt      Function        Transcript     cDNA position        Amino acid
  ------- ------------ ----- ----------- ----------- -------------------------- -------- --------------- -------------- -------------------- ----------------
  794     *ATG16L2*    11    72533157    72533157    A                          T        NS              NM_033388      c.A461T              p.E154V
          *CEP250*     20    34092235    34092235    G                          A        NS              NM_007186      c.G6038A             p.R2013Q
          *MYO1C*      17    1371330     1371330     C                          A        NS              NM_033375      c.G2743T             p.V915L
          *PNPLA2*     11    824813      824813      G                          T        NS              NM_020376      c.G1466T             p.S489I
          *TMC6*       17    76121923    76121923    C                          T        NS              NM_007267      c.C314T              p.T105M
          *ZNF521*     18    22806878    22806878    C                          T        NS              NM_015461      c.C1004T             p.P335L
  824     *ANKS1A*     6     34857302    34857302    \-                         GGCGGC   nonframeshift   NM_015245      c.123_124insGGCGGC   p.G41delinsGGG
          *BBS12*      4     123664726   123664728   AAG                        \-       nonframeshift   NM_001178007   c.1679_1681del       p.560_561del
          *C9orf66*    9     214943      214943      C                          T        NS              NM_152569      c.C454T              p.R152W
          *FAM186A*    12    50745703    50745703    T                          G        NS              NM_001145475   c.A4912C             p.T1638P
          *HIST1H1D*   6     26235127    26235127    C                          A        NS              NM_005320      c.C35A               p.P12H
          *HLA-DRB1*   6     32551957    32551957    G                          T        NS              NM_002124      c.C299A              p.A100E
          *UNC93A*     6     167728776   167728776   GT                         AC       NS              NM_018974      c.T1210C             p.F404L
  760     *DMKN*       19    36002386    36002386    C                          T        NS              NM_001126057   c.G845A              p.S282N
  772     *ZNF259*     11    116658654   116658654   G                          A        NS              NM_003904      c.C53T               p.P18L
  783     *SRA1*       5     139931629   139931629   \-                         G        frameshift      NM_001035235   c.327_328insC        p.V110fs
          *TPSAB1*     16    1291454     1291454     G                          A        NS              NM_003294      c.G253A              p.A85T
          *TPSD1*      16    1306971     1306971     A                          G        NS              NM_012217      c.A428G              p.H143R
  792     *GPC3*       X     133087197   133087197   A                          T        NS              NM_001164617   c.T217A              p.C73S
  710     *TPTE2*      13    20048214    20048214    T                          G        NS              NM_130785      c.A121C              p.I41L
  799     *CD33*       19    51729578    51729596    CCCAACAACTGGTATCTTT        \-       frameshift      NM_001772      c.711_729del         p.N237fs
  748     *PCMTD1*     8     52733228    52733228    G                          A        NS              NM_052937      c.C757T              p.R253C
          *RNASE8*     14    21526082    21526084    CTG                        \-       nonframeshift   NM_138331      c.31_33del           p.11_11del
  828     *HGC6.3*     6     168376951   168376951   T                          C        NS              NM_001129895   c.A382G              p.M128V
          *SYNJ1*      21    34003931    34003931    C                          T        NS              NM_003895      c.G4213A             p.V1405I
  844     *MADCAM1*    19    501762      501762      A                          C        NS              NM_130760      c.A761C              p.Q254P
          *NEFH*       22    29885581    29885604    AGGCCAAGTCCCCAGAGAAGGAAG   \-       nonframeshift   NM_021076      c.1952_1975del       p.651_659del

Alt, alterations; Chr, chromosome; NS, nonsynonymous; Ref, reference human genome.

RESULTS {#s2}
=======

Identification of CNC somatic genomic variations {#s2_1}
------------------------------------------------

The genomic DNAs of paired normal lung tissues and cancer tissues were sequenced to an average of 42.89× (range, 30.07×--78.70×) coverage and 66.04× (range, 61.02×--74.64×) coverage, respectively. Twenty nucleotide substitutions and 7 small insertions and deletions (indels) were found in the 11 LUADs genomes (Table [1](#T1){ref-type="table"}). Variations in 6 representative genes in the normal lung tissues were validated by RT-PCR assays and subsequent sequencing (see [Supplementary Table 1](#SD1){ref-type="supplementary-material"} for sequence of primers), and the results confirmed the existence of CNC alterations (Figure [1](#F1){ref-type="fig"}). For example, the nucleotide at chr18: 22806878 of *ZNF521* of hg19 is C; but two peaks (C and T) of approximately equal peak height were seen in sequence of normal lung tissues, whereas a high peak of C and a low peak of T were detected in tumor samples of the patient (Figure [1A](#F1){ref-type="fig"}, left panel). This change might lead to P335L substitution in the encoded protein. Sequencing results using another set of primers confirmed the existence of T in normal lung rather than counterpart tumor sample of the patient (Figure [1A](#F1){ref-type="fig"}, right panel). Nucleotide T at this position of *ZNF521* was not found in dbSNP138 common germline variants. The nucleotide at chr17: 76121923 of *TMC6* of hg19 is C; but two peaks (C and T) of approximately equal peak height were seen in sequence of normal lung tissues, whereas a high peak of C and a low peak of T were detected in tumor samples of the patient (Figure [1B](#F1){ref-type="fig"}, left panel). This change might lead to T105M substitution in the encoded protein. Sequencing results using another set of primers confirmed the existence of T in normal lung rather than counterpart tumor sample of the patient (Figure [1B](#F1){ref-type="fig"}, right panel). Similarly, the normal lung tissues had a single nucleotide change in *CEP250* (Figure [1C](#F1){ref-type="fig"}), *C9orf66* (Figure [1D](#F1){ref-type="fig"}), and *HIST1H1D* (Figure [1E](#F1){ref-type="fig"}), compared to those in the tumor samples, hg19, and dbSNP138. Substitutions of GT by AC were seen in *UNC93A* in normal lung tissue of a patient with untreated LUAD (Figure [1F](#F1){ref-type="fig"}).

![Validation of genomic variations in "normal" lung tissues\
Polymerase chain reaction (PCR) and Sanger capillary sequencing were performed using genomic DNAs of the patients and primers listed in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. Two sets of primers were used. **(A)** *ZNF521* in "normal" lung and tumor samples of the patient. **(B)** *TMC6* in "normal" lung and tumor samples of the patient. **(C)** *CEP250* in "normal" lung and tumor samples of the patient. **(D)** *C9orf66* in "normal" lung and tumor samples of the patient. **(E)** *HIST1H1D* in "normal" lung and tumor samples of the patient. **(F)** *UNC93A* in "normal" lung and tumor samples of the patient.](oncotarget-08-104113-g001){#F1}

Analyses of TCGA datasets {#s2_2}
-------------------------

To expand the above observations, the genome sequence of cancer-control paired samples from 513 patients were downloaded from TCGA datasets and carefully analyzed. Among these patients ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}), 239 (46.6%) were males and 274 (53.4%) were females, and the median age was 66 years old (range, 33 -- 88 years). Smoking history was available in 499 patients, among them 425 (85.2%) were current or reformed smokers (persons who were not smoking at the time of interview but had smoked at least 100 cigarettes in their life) and 74 (14.8%) were nonsmokers (not smoking at the time of interview and had smoked less than 100 cigarettes in their life). Adjacent normal lung tissues and peripheral blood were used as normal controls for 135 (26.3%) and 378 (73.7%) of the 513 lung adenocarcinomas, respectively.

Genomic variations were found throughout the counterpart control genomes. A mean of 0.2721 exonic variations/megabase (Mb) and 5.2885 variants/sample was recorded in the CNCs (Table [2](#T2){ref-type="table"}). The normal lung tissues had approximately equal mutations to the blood cells ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}), while males and females had equal CNC mutations ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). We compared the CNC mutations in nonsmokers, current smokers and reformed smokers, and found that smokers harbored more variations than nonsmokers, as reflected by variations/Mb ([Supplementary Figure 2A](#SD1){ref-type="supplementary-material"}), altered genes/sample ([Supplementary Figure 2B](#SD1){ref-type="supplementary-material"}), synonymous/nonsynonimous variations ([Supplementary Figure 2C](#SD1){ref-type="supplementary-material"}), and indels/sample ([Supplementary Figure 2D](#SD1){ref-type="supplementary-material"}). We also analyzed genomic mutations in tumor samples by comparing the cancer genome sequencing with reference and excluding those found in CNCs with the same calling criteria, and reported that tumor samples had much more mutations than CNCs (Table [2](#T2){ref-type="table"} and [Supplementary Figure 2E-2H](#SD1){ref-type="supplementary-material"}).

###### Genomic variations in CNCs and tumor samples of TCGA LUADs

            Exonic mutations/MB   Variant genes/sample   Nonsynonymous alterations/sample   Synonymous mutations/sample   Rearrangements/sample   
  --------- --------------------- ---------------------- ---------------------------------- ----------------------------- ----------------------- ----------
  CNC       0.2721                5.2885                 4.3723                             2.8402                        0.2378                  0.8129
  Tumor     6.0145                141.0132               135.7290                           43.6491                       6.6862                  1.9357
  P value   \<0.0001              \<0.0001               \<0.0001                           \<0.0001                      \<0.0001                \<0.0001

Nucleotide substitutions in TCGA CNC samples {#s2_3}
--------------------------------------------

Tobacco smoke contains more than 20 lung carcinogens, e.g., nicotine-derived nitrosaminoketone (NNK) \[[@R5]\] and polycyclic aromatic hydrocarbons (PAHs) which are associated with the C:G→A:T transversions in the genomes \[[@R7], [@R15], [@R16]\]. We analyzed the nucleotide substitutions in the genome, and found that the C:G→T:A and the A:T→G:C transitions were the most and the second most prevalent nucleotide substitutions in the CNCs (Figure [2A](#F2){ref-type="fig"}). In tumor samples, while the C:G→A:T transversions were the most prevalent nucleotide substitutions, the C:G→T:A transitions represented the second most prevalent nucleotide substitutions (Figure [2A](#F2){ref-type="fig"}). In CNC samples, the C:G→T:A transitions were the most prevalent nucleotide substitutions in nonsmokers, current smokers and reformed smokers (Figure [2B](#F2){ref-type="fig"}). In consistence with previous report \[[@R16]\], the C:G→T:A transitions were the most prevalent nucleotide substitutions in tumor samples of nonsmokers (Figure [2C](#F2){ref-type="fig"}), whereas the C:G→A:T transversions were the most prevalent nucleotide substitutions in tumor samples of smokers (Figure [2C](#F2){ref-type="fig"}).

![Genomic variations in the CNC samples\
**(A)** The frequency of each type of single base substitution in CNCs and tumor samples of the 513 patients with LUAD. **(B)** The proportion of nucleotide changes in CNC samples of nonsmokers, current smokers and reformed smokers. **(C)** The frequency of base substitution in tumor samples of nonsmokers, current smokers and reformed smokers. **(D)** Significantly altered genes in CNCs of the patients. CNC samples are arranged from left to right in the top track.](oncotarget-08-104113-g002){#F2}

Recurrently altered genes in CNC samples {#s2_4}
----------------------------------------

We reported that there were 16 genes which had a variation rate of more than 2% in the 513 CNCs (Figure [2D](#F2){ref-type="fig"} and [Supplementary Table 5](#SD3){ref-type="supplementary-material"}). *MUC4* represented the most frequently altered gene, which was mutated in 46/513 (8.97%) of the CNC samples (Figure [2D](#F2){ref-type="fig"}). *FAM90A1*, *ARSD*, *MADCAM1*, *ZNF814*, *CDC27*, and *HDGFRP2* were mutated in 35 (6.82%), 32 (6.24%), 26 (5.07%), 22 (4.29%), 17 (3.31%), and 16 (3.12%) of the 513 CNC samples, respectively (Figure [2D](#F2){ref-type="fig"}). *TP53*, *KRAS* and *EGFR* which were frequently mutated in LUADs \[[@R13]\], were mutated in only 2 (0.39%), 0, and 0 CNCs, respectively ([Supplementary Table 5](#SD3){ref-type="supplementary-material"}).

*MUC4* encodes an integral membrane glycoprotein found on the cell surface and plays a role in tumor progression \[[@R17]\]. We found 35 types of variations distributed throughout the entire gene of *MUC4*, including 4 recurrent ones (Figure [3](#F3){ref-type="fig"}). Frequent variations were found in *FAM90A1* \[[@R18]\], in that in all 35 patients with variant *FAM90A1*, the nucleotide G of codon (ACG) for T344 was replaced by A and a codon for valine (GUC) was inserted in 12:8374781 position at Chr 8, leading to insertion of V right after T344 (Figure [3](#F3){ref-type="fig"}). There were 67 variations in *Arylsulfatase D* (*ARSD*) gene \[[@R19]\] in 32 CNCs, with S157F, G175D, and S176K substitutions found in 9 (14.8%), 10 (16.4%), and 10 (16.4%) of the total variations. Twenty-nine alterations were found in *MADCAM1* \[[@R20]\] in 26 CNCs (Figure [3](#F3){ref-type="fig"}). Variations in *ZNF814*, *CDC27*, *HDGFRP2*, *RBMX*, *WDR66*, and *ANKRD36* in CNCs were also shown in Figure [3](#F3){ref-type="fig"}.

![Recurrent variations in some representative genes in CNCs\
Schematic representations of proteins encoded by the genes are shown. Numbers refer to amino acid residues. Each "+" corresponds to an independent, altered CNC sample. Variations within a gene indicated by a same-colored "+" are found in the same patient.](oncotarget-08-104113-g003){#F3}

Altered signaling pathways {#s2_5}
--------------------------

Pathway analysis was performed using the KEGG (Kyoto Encyclopedia of Genes and Genomes) database, and the results showed that genes involved in type I diabetes mellitus, allograft rejection, graft-versus-host disease, autoimmune thyroid disease, antigen processing and present were the most frequently altered pathways ([Supplementary Figure 3A](#SD1){ref-type="supplementary-material"}). The GO analysis confirmed that immune response genes were altered in CNC samples, and genes associated heart, muscle, and cell development were also perturbed in CNCs ([Supplementary Figure 3B](#SD1){ref-type="supplementary-material"}).

Variations associated with poor prognosis {#s2_6}
-----------------------------------------

We analyzed the potential association between the CNC variations and the prognosis of the patients using the Kaplan-Meier method, and found that variations in 8 genes were associated with the prognosis of 502 patients whose survival information was available (Figure [4](#F4){ref-type="fig"}). Sixteen variations were found in *MUC5B* in 12 (2.34%) of the 513 patients (Figure [4A](#F4){ref-type="fig"}). As compared with patients (n=490) harboring wild type *MUC5B*, those with mutant transcript had much shorter overall survival (P=0.013; Figure [4A](#F4){ref-type="fig"}). *ZXDB* \[[@R21]\] variations were seen in 10 (1.95%) of the patients, whose overall survival time was shorter than those (n=492) with wild type *ZXDB* (Figure [4A](#F4){ref-type="fig"}). Patients with variant *PLIN4* [@R22], *CCDC144NL*, *CNTNAP3B* \[[@R23]\], or *CCDC180* \[[@R24]\] in CNCs also had shorter overall survival than patients with wild type transcripts (Figure [4A](#F4){ref-type="fig"}).

![CNC variations associated with prognosis of the patients\
**(A)** Variations of MUC5B, ZXDB, PLIN4, CCDC144NL, CNTNAP3B, and CCDC180 in CNCs and Kaplan--Meier curve for overall survival of the patients with wild type or variant transcripts. Schematic representations of proteins encoded by the genes are shown. **(B)** Overall survival of patients harboring wild type or variant CHD3 or KRTAP5-5 in their CNCs.](oncotarget-08-104113-g004){#F4}

Variations in CNC samples associated with favorable prognosis of the patients {#s2_7}
-----------------------------------------------------------------------------

We found 14 variations in the *Chromodomain Helicase DNA Binding Protein 3* (*CHD3* \[[@R25]\]) gene in CNC samples of 13 (2.53%) of the 513 patients. These variations encoded proteins with P99Lsubstitution in 1 patient, I234L substitution in 8 patients, and S237P change in 5 patients (Figure [4B](#F4){ref-type="fig"}). Interestingly, none of the variant *CHD3*-bearing patients died within a follow-up of up to 2261 days, whereas the median overall survival of patients with wild type CHD3 (n=490) was 1492 days (range, 0-7248 days) (p=0.047; Figure [4B](#F4){ref-type="fig"}). Deletion mutations, i.e., deletion of codons for G41 -- G43 and G43 -- A53 of the protein product encoded by *KRTAP5-5* \[[@R26]\] gene, were found in CNCs of 10 patients. Of note, patients with variant *KRTAP5-5* had longer overall survival time than those with wild type transcript (p=0.048; Figure [4B](#F4){ref-type="fig"}).

DISCUSSION {#s3}
==========

In our work characterizing somatic mutations in air pollution-related lung cancer \[[@R7]\], we unexpectedly noted that compared to reference human genome and cancerous tissues, the normal control lung tissues also had single nucleotide variations. This was the impetus for us to conduct this study. We used the "normal-tumor pairs" method to investigate the genomic variations in CNC samples, and reported that the CNCs did harbor genomic alterations that were confirmed by Sanger capillary sequencing of PCR products (Figure [1](#F1){ref-type="fig"}). These observations were validated in TCGA lung cancer genome data. In CNC genomes of TCGA datasets, the variation rates were 0.2721 exonic variations/Mb and 5.2885 altered genes/sample, and the recurrent variants were of intermediate frequency (∼ 8.97% of the patients), whereas variations in 8 genes were associated with poor or favorable prognosis of the patients. We also dissected CNC variations in patients with lung squamous cell carcinoma, and reported a mean of 0.5661 exonic variations/Mb and 7.7887 altered genes/sample in 478 patients \[[@R27]\]. These results uncover the previously unidentified CNC variation, and suggest a role of these alterations in lung carcinogenesis.

Some human carcinogens exhibit specific mutation signatures in the genome. For instance, PAHs which are the main carcinogens of tobacco smoke and air pollution \[[@R5], [@R28]\], induce the C:G→A:T substitutions in the genome \[[@R7], [@R15], [@R16]\]. The alkylating agent N-methyl-N-nitro-N-nitrosoguanidine (MNNG) which is found in tobacco smoke and a representative molecule of the N-nitroso compounds formed in human stomach \[[@R29]\], causes the C:G→T:A nucleotide changes in the genome \[[@R15]\]. We found that in CNCs of LUADs of both the smokers and non-smokers, the C:G→T:A transitions were the predominant nucleotide changes (Figure [2A, 2B](#F2){ref-type="fig"}). In tumor samples of the patients, the C:G→T:A substitutions were the predominant nucleotide changes in non-smokers, while C:G→A:T transversions were the most frequently detected substitutions in smokers (Figure [2C](#F2){ref-type="fig"}). Though C:G→T:A substitutions may be the mutational fingerprints of ageing \[[@R30]\], these changes in CNCs may be the result of exposure to environmental carcinogens (including second hand smoke in nonsmoker) rather than a consequence of ageing, because in this study the SNPs including those of elder individuals had been filtered out. These data further suggest the key role of environmental factors in lung carcinogenesis.

The significance of these CNC variations in lung carcinogenesis remains unclear. One possibility was that some of the variant genes (e.g., *MUC4*) were pro-oncogenes, cells harboring these CNC variations were in a "precancerous" stage, and accumulation of other mutations would result in transformation and development of malignant neoplasms. Hence, cancer may have multi-clonal origins. Secondly, many of the CNC altered genes were associated with immune response ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}), which may facilitate avoiding immune destruction and cancer initiation. These possibilities warrant further investigation, and CNC variations in other types of cancers including cancers of oral, esophagus, stomach, colorectal, and liver, are worthy of further dissection.

Why CNC mutations were associated with prognosis represents an open question. We hypothesized that these observations may suggest the interactions between CNC tissues and tumor cells, constituting a micro-environment to foster or constrain cancer growth. Those CNC variations associated with poor outcome (*MUC5B*, *ZXDB*, *PLIN4*, *CCDC144NL*, *CNTNAP3B*, and *CCDC180*) may probably facilitate cancer initiation and progression, and may be a new clue to study cancer metastasis and evolution. *CHD3* encodes a chromatin-remodeling factor to repress transcription and is involved in breast cancer \[[@R31]\]. *KRTAP5-5* is an oncogene regulating cancer cell motility and vascular invasion \[[@R32]\]. Whether variations in these two genes modulate transcription machinery or tumor microenvironment to constrain cancer and thus contribute to favorable prognosis, needs to be determined. In addition, how to target the CNC variations to develop novel therapeutics represents another open question.

MATERIALS AND METHODS {#s4}
=====================

Patients, whole genome sequencing, and validation by Sanger capillary sequencing {#s4_1}
--------------------------------------------------------------------------------

The aim of this study was to address whether there is any genomic alteration in CNCs rather than counterpart tumor tissues ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). This study was approved by the research ethics committee of our institute. Genomic DNAs were isolated from normal lung tissues (5 cm or more away from the tumors) and adjacent tumors of 11 patients with previously untreated LUAD, the sequencing libraries were constructed, and sequenced using the Illumina Hiseq2000 platform \[[@R7]\]. The genome sequences of counterpart normal lung tissues were analyzed by the Genome Analysis Toolkit (GATK) \[[@R33]\] UnifiedGenotyper and VarScan, compared with a reference human genome (hg19, downloaded from <http://genome.ucsc.edu/>) \[[@R34]\] and filtered against dbSNP138 common germline variants (downloaded from <http://genome.ucsc.edu/>) and those also detected in tumor samples. Variants from sequencing artifacts were removed by VarScan fpfilter. The following criteria were used to call variations: average base quality ≥ 20, average mapping quality ≥ 20, depth ≥ 6, and variant allele frequency in counterpart sample ≥ 0.20 and ≤ 0.05 in tumor sample. The called variations were validated by polymerase chain reaction (PCR) and Sanger capillary sequencing using genomic DNAs of the patients and primers listed in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. Mutations in cancer genome were also analyzed by the GATK using the above criteria.

Analyses of TCGA LUAD genome data {#s4_2}
---------------------------------

The TCGA genome data of 513 LUADs (Table [1](#T1){ref-type="table"}) were downloaded from the Cancer Genomics Hub (CGHub) (<https://cghub.ucsc.edu/>) with approval by the National Institutes of Health (NIH; approval number \#24437-4), and analyzed by GATK using the criteria for CNC variants.

Statistics {#s4_3}
----------

All of the values were evaluated using the SPSS 17.0 software for Windows (SPSS Inc., Chicago, Illinois). Statistically significant differences were determined by Student's *t*-test, and the survival curves were plotted according to the Kaplan-Meier method and compared by the log-rank test. *P* values less than 0.05 were considered statistically significant in all cases.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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